An outstanding CME day will be held the first day of the annual ERA-EDTA Congress (June 13, 2019), with 13 Courses offering the best of what is available, from an educational point of view, to our delegates.
Introductory Course on Epidemiology – PRE ‘AFRAN Congress Course’
SEPTEMBER 25 – 28, 2019 – MOMBASA, KENYA
Many nephrologists perform some kind of research in addition to their clinical duties. This one-day introductory epidemiology course is organised as a pre-congress CME of the AFRAN congress which will be held from September 25-28, 2019 in Mombasa, Kenya. The aim of the course is to teach African nephrologists and nephrology researchers, basic epidemiology principles and to have them practise their new skills in hands-on sessions (exercises, discussions and SPSS). The knowledge and skills obtained will assist participants to improve the quality of their nephrology research.
Starting from 2019 ERA-EDTA has decided to create a special Scientific and Educational Interaction Day to encourage ERA-EDTA Scientific Committees to develop joint project proposals by forming alliances, fostering international collaborations and integrating different (sub-)specialties. The first SEID will be held in Vienna, Austria on October 25-26, 2019.
Diabetes and Obesity in Renal Disease in 2019, an update
NOVEMBER 15-16 – MADRID, SPAIN
The fast growing prevalence of obesity, metabolic syndrome and type 2 diabetes is an important challenge in nephrology. These entities are deeply interrelated. In fact, obesity and metabolic syndrome frequently precede diabetes. Also, overweight, obesity, hypertension, dyslipidemia, pre-diabetes and diabetes are risk factors for renal disease. Obesity itself can cause specific renal disease such as obesity-related glomerulopathy or increase the risk for progression of kidney diseases irrespective of the underlying cause. The pathways involved in renal disease associated with obesity, metabolic syndrome and diabetes are not completely known. Renal lipotoxicity and inflammation are major areas of research and could be involved in renal damage in these metabolic complications. Evidence of complementary small and large animal models may help to understand renal disease in these conditions. Finally, recent evidence in cardiovascular and renal protection of specific diets and new medications seem to offer promising alternatives to patients with type 2 diabetes and renal disease. All these topics will be discussed in the new meeting of DIABESITY, a working group of the ERA-EDTA.